Current Report Filing (8-k)
June 16 2017 - 1:31PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 16, 2017
Cigna Corporation
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
1‑08323
(Commission File Number)
|
06‑1059331
(IRS Employer
Identification No.)
|
900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(860) 226-6000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-49(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
On June 16, 2017, Cigna Corporation ("Cigna") received notification from the Centers for Medicare & Medicaid Services ("CMS") that the marketing and enrollment sanctions imposed by CMS on January 21, 2016, have been lifted. Effective immediately, Cigna may resume marketing of its Medicare Advantage-Prescription Drug and Medicare Part D Plans and may begin enrolling beneficiaries with effective dates beginning July 1, 2017.
In addition, based on the final Medicare Star Ratings for the 2018 payment year, we expect that approximately 60% of our Medicare Advantage customers will be in a 4 Star or greater plan.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cigna Corporation
|
|
|
|
|
|
|
Date: June 16, 2017
|
By:
|
/s/ Nicole S. Jones
|
|
|
Nicole S. Jones
|
|
|
Executive Vice President and
|
|
|
General Counsel
|
Cigna (NYSE:CI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Sep 2023 to Sep 2024